Talazoparib Is Active in gBRCA1/2 Mutation-Positive, HER2-Negative Early Breast Cancer
Researchers evaluated the efficacy and safety of talazoparib in the neoadjuvant setting in a phase 2, nonrandomized, single-arm, open-label study.
All articles by Walter Alexander
Durvalumab Improves Survival When Added to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
Durvalumab improved invasive disease-free survival, distant disease-free survival, and overall survival.
Genomic Signature May Identify Breast Cancer Patients Who Can Safely Forgo Adjuvant Radiotherapy
The signature was prognostic for locoregional recurrence.
Chemotherapy Doesn’t Increase the Risk of COVID-19 or Related Death in Patients with Breast Cancer, Study Suggests
Rates of SARS-CoV-2 infection and COVID-19-related death were similar among patients receiving cytotoxic and non-cytotoxic therapy.
Endocrine Therapy Proves Noninferior to Chemotherapy in HR+, HER2+ Metastatic Breast Cancer
Endocrine therapy was associated with fewer adverse events.
Age and Stage at Breast Cancer Diagnosis Don’t Account for Racial Disparities in Distant Metastases
Black patients were more likely than White patients to have distant metastases.
LEAP-004: Durable Responses in Advanced Melanoma Achieved With Lenvatinib Plus Pembrolizumab
In patients with melanoma and confirmed progression on a PD-1, lenvatinib plus pembrolizumab demonstrated clinically meaningful responses.
Neoadjuvant Nivolumab Plus Relatlimab Produced a High pCR Rate in Stage III-IV Melanoma
Rates of relapse-free and overall survival were high as well, exceeding 90%.
Greater Benefit With Pembrolizumab in Crossover vs Rechallenged Patients With Cutaneous Melanoma
Patients were more likely to benefit from pembrolizumab if they had not previously received the drug.
Adjuvant Pembrolizumab Improves RFS, Not OS, in Resected High-Risk Melanoma
Pembrolizumab bested high-dose interferon alfa-2b and high-dose ipilimumab.
- Loading...
Loading...
Loading... 
Loading...